Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BeiGene, Ltd.    BGNE

BEIGENE, LTD.

(BGNE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/21/2020 10/22/2020 10/23/2020 10/26/2020 10/27/2020 Date
302.57(c) 303.79(c) 299(c) 301.28(c) 300.77 Last
154 372 238 052 239 014 88 344 151 776 Volume
+0.89% +0.40% -1.58% +0.76% -0.17% Change
More quotes
Financials (USD)
Sales 2020 339 M - -
Net income 2020 -1 361 M - -
Net cash position 2020 3 129 M - -
P/E ratio 2020 -22,5x
Yield 2020 -
Sales 2021 716 M - -
Net income 2021 -1 065 M - -
Net cash position 2021 1 809 M - -
P/E ratio 2021 -26,0x
Yield 2021 -
Capitalization 27 097 M 27 097 M -
EV / Sales 2020 70,8x
EV / Sales 2021 35,3x
Nbr of Employees 4 200
Free-Float 69,8%
More Financials
Company
BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290). 
More about the company
Notations Surperformance© of BeiGene, Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about BEIGENE, LTD.
10/07BEIGENE : BioAtla and BeiGene Revise Global Development and Commercialization Ag..
AQ
10/07BEIGENE : BioAtla and BeiGene Revise Global Development and Commercialization Ag..
AQ
10/06BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/06BEIGENE : BioAtla and BeiGene Revise Global Development and Commercialization Ag..
BU
10/02BEIGENE, LTD. : Termination of a Material Definitive Agreement, Financial Statem..
AQ
09/24BEIGENE, LTD. : Entry into a Material Definitive Agreement, Financial Statements..
AQ
09/23BEIGENE : 2020 Interim Report
PU
09/22LEAP THERAPEUTICS : and BeiGene Announce First Patient Dosed in Study of DKN-01 ..
AQ
09/21BEIGENE, LTD. : Other Events (form 8-K)
AQ
09/20BEIGENE : Next Day Disclosure Return
PU
09/18BEIGENE : Voluntary announcement - update regarding recent business developments
PU
09/18BEIGENE : Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislel..
AQ
09/17BEIGENE : Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislel..
BU
09/15BEIGENE : Next Day Disclosure Return
PU
09/13BEIGENE : Next Day Disclosure Return
PU
More news
News in other languages on BEIGENE, LTD.
09/19BEIGENE : präsentiert auf dem ESMO Virtual Congress 2020 Ergebnisse der Phase-3-..
09/18BEIGENE : présente au congrès virtuel 2020 de l'ESMO des données sur l'essai de ..
01/03LEAP THERAPEUTICS, INC. : annonce un pacte avec BeiGene
More news
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Average target price 241,89 $
Last Close Price 299,00 $
Spread / Highest target 5,69%
Spread / Average Target -19,1%
Spread / Lowest Target -47,2%
EPS Revisions
Managers
NameTitle
John V. Oyler Chairman & Chief Executive Officer
Xiao Bin Wu President & General Manager-China Region
Howard Liang Chief Financial & Strategy Officer
Jane E. Huang Chief Medical Officer-Hematology
Yong Ben Chief Medical Officer-Immuno & Oncology Department
Sector and Competitors
1st jan.Capitalization (M$)
BEIGENE, LTD.80.38%27 097
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.58.33%37 775
GENMAB A/S49.17%22 988